Page last updated: 2024-11-12
bedoradrine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
bedoradrine: structure in first source; RN given is for sulfate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9963057 |
CHEMBL ID | 2111083 |
SCHEMBL ID | 3828780 |
MeSH ID | M0497762 |
Synonyms (18)
Synonym |
---|
unii-4ear229231 |
bedoradrine [inn] |
194785-19-8 |
4ear229231 , |
bdbm85786 |
bedoradrine |
(-)-2-[(2s)-2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-1,2,3,4-tetrahydronaphthalen-7-yloxy]-n,n-dimethylacetamide |
OANCEOSLKSTLTA-REWPJTCUSA-N |
2-(((7s)-7-(((2r)-2-hydroxy-2-(4-hydroxy-3-(2-hydroxyethyl)phenyl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)-n,n-dimethylacetamide |
kur-1246 free base |
mn-221 free base |
acetamide, n,n-dimethyl-2-(((7s)-5,6,7,8-tetrahydro-7-(((2r)-2-hydroxy-2-(4-hydroxy-3-(2-hydroxyethyl)phenyl)ethyl)amino)-2-naphthalenyl)oxy)- |
SCHEMBL3828780 |
CHEMBL2111083 |
DTXSID60173123 |
DB05590 |
2-[[(7s)-7-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-n,n-dimethylacetamide |
Q27259486 |
Research Excerpts
Overview
Bedoradrine is a promising drug for the treatment of preterm labor in obstetrical practice. It has better selectivity for beta(2)-AR and specificity for the uterus than currently used agents and may effectively delay spontaneous delivery.
Excerpt | Reference | Relevance |
---|---|---|
"Bedoradrine is a promising drug for the treatment of preterm labor in obstetrical practice because it has better selectivity for beta(2)-AR and specificity for the uterus than currently used agents and may effectively delay spontaneous delivery." | ( Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. Inoue, Y; Kawarabayashi, T; Yoshizato, T, 2009) | 2.02 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (13)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (61.54) | 29.6817 |
2010's | 5 (38.46) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.64
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.64) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (15.38%) | 5.53% |
Reviews | 2 (15.38%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (69.23%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |